Clinical Trial

AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral…

2 months ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — —…

2 months ago

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy

Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of…

2 months ago

BIOPHYLE LAUNCHING COMMERCIALIZATION TRAINING PROGRAM FOR ARKANSAS LIFE SCIENCE RESEARCHERS

BENTONVILLE, Ark., Sept. 23, 2024 /PRNewswire/ -- biophyle—a not-for-profit educational institution fostering collaboration between scientists and clinicians in Arkansas and…

2 months ago

Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren’s Syndrome, a Rare Disease With Limited Treatment Options

Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretionAinos aims to complete all regulatory approvals for…

2 months ago

Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine ProceduresBELGRADE, MT / ACCESSWIRE / September 23, 2024…

2 months ago

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –…

2 months ago

Interim Results for the Six Months Ended 30 June 2024

Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued…

2 months ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024…

2 months ago

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UKSAN DIEGO, Sept. 23, 2024…

2 months ago